BELLUS Health  logo
BELLUS Health BLU

Annual report 2022
added 12-28-2024

report update icon

BELLUS Health EBITDA 2011-2026 | BLU

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA BELLUS Health

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- -73.3 M -32.9 M -25.7 M - -4.46 M -1.51 M 28.1 K -1.78 M -2.43 M -21.1 M -1.71 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
28.1 K -73.3 M -16.5 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
3.11 B - - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
1.19 M $ 0.89 - $ 6.54 M chinaChina
Biophytis SA Biophytis SA
BPTS
-26.8 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
31.8 M - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
232 M $ 22.35 0.68 % $ 3.7 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-124 M - - $ 10.1 M usaUSA
Advaxis Advaxis
ADXS
-35.9 M - -9.65 % $ 45.9 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.67 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-23.9 M - -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
15.3 B $ 103.69 2.08 % $ 27.2 B germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-9.75 M - -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-16.2 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-55.6 M - 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-47.8 M $ 1.48 -0.67 % $ 235 M franceFrance
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
-190 M - - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
-46.1 M - 4.14 % $ 49.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-9.93 M $ 3.65 22.48 % $ 6.01 M israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
122 K - -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
Applied Therapeutics Applied Therapeutics
APLT
-64.5 M - - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
22 K - -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
-70.5 M $ 4.08 0.74 % $ 436 M usaUSA
Aptinyx Aptinyx
APTX
-62.4 M - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
-70 M - -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-29.5 M - 17.91 % $ 11.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
-11.5 M $ 22.65 1.25 % $ 2.88 B usaUSA
Edesa Biotech Edesa Biotech
EDSA
-6.83 M $ 16.23 2.08 % $ 51.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-47.3 M - 3.16 % $ 1.9 M usaUSA
Athira Pharma Athira Pharma
ATHA
-101 M - - $ 269 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-57.6 M - - $ 2.17 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.08 M - -52.27 % $ 4.45 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-50.6 M - 10.36 % $ 9.8 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-262 M $ 1.42 0.71 % $ 378 M britainBritain
AVROBIO AVROBIO
AVRO
10.8 M - 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-37.3 M - - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
1.06 B - - $ 96.9 B britainBritain
Evogene Ltd. Evogene Ltd.
EVGN
-31 M $ 0.79 4.79 % $ 27.9 M israelIsrael
Atreca Atreca
BCEL
5.46 M - -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
37.3 M - -4.8 % $ 255 M usaUSA
Exelixis Exelixis
EXEL
901 M $ 45.0 0.69 % $ 12.2 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
589 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Завод ДИОД Завод ДИОД
DIOD
85.9 M - - - russiaRussia